The Wnt/β-catenin signalling pathway is known to play a vital role in the maintenance of cancer stem cells (CSCs), which are reported to be the origine of malignant cancers, and result in poor prognosis of multiple kinds of cancer. Therefore, it is of great importance to illuminate the mechanism by which the Wnt/β-catenin pathway regulates the cancer stem cell-like traits in cancers. Here, we report that miR-942 is significantly upregulated in esophageal squamous cell carcinoma (ESCC), and miR-942 levels are associated with poor prognosis in ESCC patients. Overexpression of miR-942 promotes, whereas inhibition of miR-942 decreases, the tumor sphere formation, the CD90 + subpopulation cells and the expression of pluripotency associated markers. Moreover, in vivo assay shows that miR-942 overexpressing cells form larger tumors and display higher tumourigenesis. Furthermore, we demonstrate that miR-942 upregulates the Wnt/β-catenin signaling activity via directly targeting sFRP4, GSK3β and TLE1, which are multiple level negative regulators of the Wnt/β-catenin signaling cascade. In addition, our results indicate that c-myc directly binds to the miR-942 promoter and promotes its expression. Taken together, our findings establish an oncogenic role of miR-942 in ESCC and indicate that miR-942 might be an effective therapeutic target for ESCC.
chemotherapy and radiotherapy [5, 6] . Several studies have reported that CSCs play a vital role in esophageal squamous cell carcinoma (ESCC) progression. For example, Forghanifard et al. found that SALL4 and SOX2, which are stemness state transcriptional factors involving in maintenance of pluripotency and self-renewal, played vital role in ESCC progression [7] . Zhao and colleagues have demonstrated the stem cell-like side populations are a source of chemo-resistance and metastasis in esophageal cancer [8] . Therefore, targeting CSCs could be an effective treatment for ESCC therapy. And it is vital to understand the molecular mechanisms of which control CSCs in ESCC.
The Wnt/β-catenin signalling pathway, a key molecular pathway controlling the function of stem cells, has been shown to play an important role in CSCs [9] [10] [11] . The canonical Wnt/β-catenin signaling is stimulated by the secreted Wnt ligands, which bind to the Frizzled (FZD) family receptors and LRP5/LRP6 co-receptor to trigger the β-catenin signalling cascade. Receptors activation leads to the phosphorylation of Dishevelled (Dvl), and consequently release β-catenin from the "destruction complex" -Axin, adenomatous polyposis coli (APC), casein kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β). Thereby, β-catenin translocates to the nucleus and binds to the N-terminal of the TCF/LEF transcriptional factor, thus activating downstream target genes [12] [13] [14] . The Wnt/β-catenin pathway has been shown to be constitutively activated in various types of cancer, leading to cell reprogramming and generation of a stem-like phenotype [15, 16] . Numerous studies have shown that Wnt/β-catenin signalling is hyperactivated in multiple cancers [12, 17] . In colon cancer, inappropriate permanent activation of the Wnt cascade always due to the loss of APC allele, Axin mutation or activating β-catenin point mutation [17, 18] . Tanaka et al. have reported that a novel member of the human frizzled (FzD) gene family FzE3 was expressed only in esophageal cancer tissues, but not in adjacent normal tissues [19] .
On the other hand, dysregulation of negative regulators could also contribute to constitutive activation of the Wnt/β-catenin signalling in cancer. These negative regulators are involved in three layers in Wnt/β-catenin signalling: extracellular secreted Wnt inhibitors, such as the secreted Frizzled-related proteins (sFRPs), which serve as Wnt antagonists and inhibit Wnt binding to Frizzled receptors [20] [21] [22] ; intracellular canonical Wnt inhibitorsAxin, adenomatous polyposis coli (APC), casein kinase 1α (CK1α), and glycogen synthase kinase 3β (GSK3β), which form the destruction complex and prevent β-catenin from translocating into the cell nucleus [23] ; and nuclear transcriptional suppressors, such as TLE1, NLK and CtBP2, which inhibit the transcriptional activity of LEF/ TCF [24] [25] [26] . However, how these negative regulators of the Wnt/β-catenin signalling pathway are concomitantly deregulated in cancer is largely unclear.
In the present study, we found that the microRNA miR-942 was markedly overexpressed in ESCC and promoted the stem cell-like traits by inhibition of three negative regulators of Wnt/β-catenin pathway, including sFRP4, GSK3β and TLE1. Therefore, our results suggest that miR-942 might be a potential therapeutic target for ESCC.
rEsULts

mir-942 overexpression correlates with Escc progression
By analysis the Cancer Genome Atlas (TCGA) microarray data set consisting of 177 primary esophageal cancer tissues and 13 normal esophageal tissues, miR-942 was significantly upregulated in tumour tissues compared to normal tissues ( Fig. 1A and Supplementary Fig. 1 ). Furthermore, real-time PCR analysis showed that miR-942 was ubiquitously overexpressed in 10 ESCC samples compared with the paired normal tissues and in all 12 ESCC cell lines compared with 2 NEECs (Fig. 1B and  1C) . Collectively, these findings suggested that miR-942 expression is significantly increased in ESCC.
The observed upregulation of miR-942 prompted us to further investigate the clinical relevance of miR-942 in ESCC progression. We therefore examined miR-942 expression in a cohort of 158 archived human ESCC specimens (Supplementary Table 1 ). Statistical analysis revealed that miR-942 expression was positively correlated with clinical stage (P < 0.001), tumour-node-metastasis (TNM) classification (T: P = 0.005; N: P < 0.001; M: P = 0.004), and histologic differentiation (P = 0.045) in patients with ESCC (Fig. 1D and Supplementary Table  2) . Importantly, patients with higher miR-942 expression had a shorter survival time, whereas patients with lower miR-942 expression had a longer survival time (P = 0.01; Fig. 1E ). Moreover, Univariate and multivariate analyses indicated that miR-942 expression and clinical stage were independent prognostic factors in ESCC (Supplementary  Table 3 ). Taken together, these results indicate a possible link between miR-942 overexpression and human ESCC progression.
Upregulation of mir-942 promotes cancer stem cell-like traits in Escc
In attempt to understand the biological effect of miR-942 in ESCC progression, miR-942 was stably transduced into the Eca109 and Kyse510 ESCC cell lines to generate Eca109/miR-942 and Kyse510/miR-942 cell lines ( Supplementary Fig. 2A) . A tumour sphere formation assay showed that miR-942-transduced cells formed more and larger spheres than vector-tranduced www.impactjournals.com/oncotarget Transcript levels were normalized by U6 expression. The boundaries of the boxes represent the lower and upper quartiles; lines within boxes and whiskers denote median and extremum, respectively. * P < 0.05 (E) Kaplan-Meier curves of ESCC patients with low-versus high-expression of miR-942 (n = 158; P <0.001, log-rank test). cells ( Fig. 2A and 2B) . Additionally, CD90 positive cells, which were well-known esophageal CSC marker, were dramatically increased in miR-942-transduced cells compared with vector-tranduced cells (Fig. 2C) . Furthermore, miR-942 overexpression significantly upregulated the mRNA expression levels of multiple pluripotency factors, including ABCG2, KLF4, SOX2, OCT4, and NANOG (Fig. 2D) . However, the proliferative rate of miR-942-transduced Eca109 and Kyse510 cells is only slightly quick compare to the vector control cells (Fig. 2E) . Collectively, our results suggest that miR-942 overexpression promotes the stem cell-like traits of ESCC cells.
mir-942 inhibition suppresses Escc stem celllike traits
To examine the role of endogenous miR-942 in ESCC stem cell -like traits, antagomir-942, an antisense-based specific inhibitor against miR-942, was applied as antagonists to silence endogenous miR-942 ( Supplementary Fig. 2B ). As shown in Fig. 3A and 3B, the tumour sphere formation assay revealed that when + cells using flow cytometric analysis. * P < 0.05 (D) Real-time PCR analysis of the mRNA expression of pluripotency-associated markers in the indicated cells. Transcript levels were normalized to GAPDH expression. Error bars represent mean ± SD from three independent experiments. *P < 0.05 (E) MTT assay revealed that miR-942 overexpression is only slightly quick in Eca109 and Kyse510 stable cell lines compare to the vector control cells at indicated times after seeding. www.impactjournals.com/oncotarget miR-942 was inhibited, the cells formed fewer and smaller spheres. Similarly, CD90 population was dramatically decreased in antagomir-942 cells compared with control cells (Fig. 3C) . Furthermore, miR-942 inhibition significantly decreased the mRNA expreesion of ABCG2, KLF4, SOX2, OCT4, and NANOG (Fig. 3D) . However, inhibition of miR-942 is only slightly suppressed in Eca109 and Kyse510 compare to the control cells (Fig.  3E) . Thus, our experiments indicated that endogenous miR-942 might act as a cancer stem cell inducer which promotes ESCC stem cell-like traits.
Upregulation of mir-942 promotes tumourigenecity of Escc cells in vivo
The biological effect of miR-942 on ESCC progression was further examined using an in vivo tumour model. Eca109/miR-942 or Eca109/vector cells were subcutaneously xenografted into the NOD/SCID mice. As shown in Fig. 4A -D, the tumours formed by Eca109/ 
miR-942 directly targets sFRP4, GSK3β, and tLE1
As Wnt/β-catenin signalling pathways is the major molecular pathway controlling CSCs and promotes tumour progression [27] , we hypothesis miR-942 might regulate Wnt/β-catenin signalling. As expected, miR-942 overexpression markedly increased the luciferase activity of the TOP flash/ FOP flash reporter. Conversely, transfection of antagomir-942 reduced the luciferase activity, and mutant miR-942 had no effect (Fig. 5A) , indicating that miR-942 activates Wnt/β-catenin signalling. Using publicly available algorithms (TargetScan6.2 and miRanda), we found that sFRP4, GSK3β, and TLE1, the multiple negative regulators of Wnt/β-catenin pathway, might be the potential targets of miR-942 (Fig. 5B) . Western blot analysis revealed that the expressions of sFRP4, GSK3β, and TLE1 was drastically decreased in miR-942-transduced cells but pronouncedly elevated in antagomir-942 cells, compared with their corresponding control cells (Fig. 5C ). In addition, results of the luciferase reporter activities, which linked to the 3'UTRs of sFRP4, GSK3β, and TLE1, indicated that miR-942 overexpression significantly repressed, whereas inhibition of endogenous miR-942 increased, the luciferase activity of 3'UTRs, and ectopically expressing mutant miR-942 had no inhibitory effect on the 3'UTRs luciferase activity (Fig. 5D) . Importantly, results of the miRNP immunoprecipitation assay showed that miR-942 selectively associated with sFRP4, GSK3β, and TLE1, but not GAPDH or 5s rRNA (Fig. 5E) . Hence, our results indicate that sFRP4, GSK3β, and TLE1 are the bona fide targets of miR-942.
mir-942 maintains cancer stemness via activating Wnt/β-catenin signalling pathway
Since sFRP4, GSK3β, and TLE1 are important negative regulators of the Wnt/β-catenin pathway, we then examined the effect of miR-942 on the Wnt/β-catenin pathway. Western blot analysis proved that miR-942 overexpression induced, wheras miR-942 inhibition decreased, the nuclear accumulation of β-catenin (Fig. 5C ).
To explore the functional significance of sFRP4, GSK3β, and TLE1 in stem cell-like traits and β-catenin activation induced by miR-942, we silenced the endogenous sFRP4, GSK3β, and TLE1 using siRNAs in antagomir-942 cells (Supplementary Fig. 3 ). As shown in Fig. 5F and 5G, individually silencing sFRP4, GSK3β, or TLE1 increased the tumour sphere formation and enhanced the TOP flash/ FOP flash activity of antagomir-942 cells. These results demonstated that sFRP4, GSK3β, and TLE1 are important for miR-942-induced stem cell-like traits and indicated that Wnt/β-catenin signalling is a functional mediator for miR-942-induced function in ESCC cell lines.
mir-942 is upregulated by c-myc and clinically correlated with c-myc and β-catenin
To determine the mechanism of miR-942 upregulation in ESCC, the miR-942 promoter region was analysed using the UCSC genome browser (http:// genome.ucsc.edu/), and two binding sites for c-myc (E-box1 and E-box2) were predicted on the promoter of miR-942 (Fig. 6A) . Real-time PCR indicated that miR-942 was upregulated in c-myc-elevated cells and was downregulated in c-myc-silenced cells (Fig. 6B) . Furthermore, a dual-luciferase reporter assay showed that c-myc obviously activates miR-942 through binding to the first E-box (E-box1) (Fig. 6B) . Meanwhile, when mutated the second E-box, no obvious alterations were observed. Moreover, chromatin immunoprecipitation (CHIP) assays showed high binding affinity of endogenous c-myc with the first E-box region (Fig. 6C) . Collectively, our results indicated that c-myc directly binds to the promoter of miR-942 and promotes its expression. Finally, using 10 freshly collected clinical ESCC samples, miR-942 expression was shown to be positively correlated with c-myc (r = 0.723, P = 0.01), nuclear β-catenin expression (r = 0.774, P = 0.03) (Fig. 6D and 6E) , further supporting the notion that miR-942 is upregulated by c-myc and promoted stem-cell like traits by activating Wnt/β-catenin signalling in ESCC.
DIscUssION
To our knowledge, the present study is the first time to show the central role of miR-942 in promoting ESCC tumourigenesis. Using microRNA screening and realtime PCR assays, we found that miR-942 was strongly overexpressed in ESCC and was positively correlated with poor prognosis in this cancer. Further, miR-942 induced ESCC stem-like traits through directly targeting sFRP4, GSK3β and TLE1, which are important negative regulators of the Wnt/β-catenin pathway. Moreover, c-myc was found to directly bind to miR-942 promoter and upregulates miR-942 expression. Taken together, our results revealed a novel mechanism by which miR-942 regulates ESCC stem cell-like traits through activating the www.impactjournals.com/oncotarget Wnt/β-catenin pathway, suggesting that miR-942 might function as a therapeutic target for ESCC.
Esophageal cancer is one of the most aggressive cancers which ranks as the sixth cause of cancer-related deaths worldwide [28] . Esophageal squamous cell carcinoma (ESCC) occuring in the middle or upper third of the esophageal, and adenocarcinoma (EAC) occuring in the distant third or oesophgogastric junction, are the two major histologic subtypes of esophageal cancer. ESCC leads to significant morbidity and mortality in developing countries, such as China and Iran, where approximately 90% of all cases of esophageal cancer are ESCC [29] . Surgical resection combines with neoadjuvant chemoor radio-therapy, are the common therapeutic methods used nowadays. However, despite advances in medical diagnosis and treatment, the prognosis of ESCC has not significantly improved, and the 5-year survival rate for ESCC patients ranges only between 15% and 40%. The most important reason results in poor prognosis of ESCC always due to delayed diagnosis, metastasis, highly relapse rate and a limited understanding of the cellular and molecular mechanisms underlying the initiation, promotion, and progression of ESCC. Nowadays, multiple researchers have proved that the existence of CSCs could lead to therapeautic failure of ESCC [30] . Therefore, targeting CSCs might develop be an effective strategy for cancer therapy, and it is important to explore the properities of CSCs [31, 32] .
The Wnt/β-catenin signalling pathway is a wellknown pathway involved in regulating self-renewal and oncogenesis in many systems [33, 34] . In normal physiological state, the Wnt/β-catenin signalling pathway regulates downstream genes involved in basic cellular processes, such as cell proliferation, differentiation, migration and cell death [35, 36] . It means that the Wnt/β-catenin signalling should be kept in a normal level to exert normal physiological function. However, extensive findings have shown that the Wnt/β-catenin pathway is constitutively activated in many cancers [37] . Understanding the underlying mechanisms is important in for cancer therapy. In the present study, we found miR-942 activates Wnt/β-catenin pathway in different layers through directly downregulation of sFRP4, GSK3β, and TLE1. Therefore, our results uncover a novel mechanism in which Wnt/β-catenin pathway constitutively activates in cancer.
sFRP4 is hommologous to the extracellular cysteinerich domain of frizzled, which is a putative Wnt-binding receptor [38] . Through interaction and inhibition of Wnt ligand, sFRP4 exert antagonistic activity in Wnt/β-catenin pathway, suggesting that sFRP4 might be a tumour suppressor [39] . Consistently, sFRP4 has been found to be downregulated in several human cancers. Carmon et al. reported that sFRP4 was significantly decreased in endometrial cancer cells and inhibited cell growth [20] . Meanwhile, sFRP4 increases chemotherapeutic sensitivity in glioma stem-like cells and induces apoptosis via inhibiting Wnt/β-catenin signalling [40] . It has been reported that the protein expression of sFRP4 was downregulated through promoter CpG island methylation in colorectal cancer, mesothelioma, cervical cancer and leukemia [41] [42] [43] [44] . However, Zinovyeva and his colleagues showed that the mRNA expression of sFRP4 was higher in ESCC than in normal cells [45] , the molecular mechanism underlying sFRP4 protein downregulation in ESCC remained largely unclear. In the current study, we demonstrated first time that miR-942 directly targets the sFRP4-3'UTR, thereby inhibiting sFRP4 protein expression.
In summary, our studies demonstrated that overexpression of miR-942 prmotes stem cell-like traits and tumourigenesis in ESCC by directly suppressing sFRP4, GSK3β, and TLE1, which are multiple negative regulators of Wnt/β-catenin signalling. Our findings reveal a novel molecular mechanism to explain how constitutive activation of the Wnt/β-catenin pathway is maintained in cancers and suggests that miR-942 might serve as a potential therapeutic target for ESCC.
MAtErIALs AND MEtHODs cells
Primary cultures of normal esophageal epithelial cells (NEECs) were established from fresh specimens of the adjacent noncancerous esophageal tissue taken from an area over 5 cm from the cancerous tissue, according to previous report [46] . The esophageal cancer cell lines, including Kyse140, Kyse180, Kyse30, Kyse410, Kyse510, Kyse520, Eca109, TE-1, EC18, EC9706, HKESC1 and 108CA were grown in the DMEM medium (Invitrogen, Carlsbad, CA) supplemented with 10% fetal bovine serum (HyClone, Logan, UT). 
Patient information and tissue specimens
Primers and oligonucleotides
Vectors, retroviral infection and transfection
The human miR-942 gene was PCR-amplified from genomic DNA and cloned into a pMSCV-puro retroviral vector. pMSCV-miR-942 was cotransfected with the pIK packaging plasmid in HEK293T cells using the standard calcium phosphate transfection method. Thirty-six hours after the cotransfection, supernatants were collected and incubated with cells to be infected for 24 hours in the presence of polybrene (2.5 μg/ml). After infection, puromycin (0.5 μg/ml) was used to select stably transduced cells over a 10-day period [47] . The reporter plasmids containing wild-type (CCTTTGATC; TOP flash) or mutated (CCTTTGGCC; FOP flash) TCF/ LEF DNA binding sites were purchased from Upstate Biotechnology (New York, USA). The 3'UTRs of sFRP4, GSK3β, and TLE1, respectively, were amplified and cloned downstream to the luciferase gene in a modified pGL3 control vector. Antagomir-942 was purchased from RIBOBIO Company (Guangzhou, China).
Luciferase reporter assay
Cells (3× 10 4) were seeded in triplicate in 24-well plates. 24-hours later, indicated luciferase reporter plasmids plus 3 ng pRL-TK Renilla plasmid were transfected into the cells using Lipofectamine 2000 Reagent (Life Technologies, USA). 48 hours after transfection, Dual Luciferase Reporter Assay (Promega, USA) was performed according to the manufacturer's instructions.
Western blot analysis
Western blot analysis was performed using anti-sFRP4 (1:2000, Abcam, Cambridge, MA, USA); anti-GSK3β (1:5000, Abcam, Cambridge, MA, USA), anti-TLE1 (1:3000, Abcam, Cambridge, MA, USA); anti-β-catenin (1:5000, Abcam, Cambridge, MA, USA); anti-cmyc (1:1000, Abcam, Cambridge, MA, USA). To control sample loading, the blotting membranes were stripped and re-probed with an anti-α-tubulin or anti-p84 antibody (1:5000, Sigma, Saint Louis, MO, USA). Nuclear extracts were prepared using the Nuclear Extraction Kit (Active Motif), according to the manufacturer's instructions.
mirNP immunoprecipitation
Cells were co-transfected with HA-Ago1 together with 100 nM miR-942, followed by HA-Ago1 immunoprecipitation using HA-antibody. Real-time PCR analysis of the IP material was used to test the association of the mRNA of sFRP4, GSK3β, and TLE1 with the RISC complex. ) in the right dorsal flank per mouse. For in vivo antagomir assay, 1x10 6 Eca109 cells were inoculated subcutaneously in the left dorsal flank of BALB/c nude mice. 7 days later, one hundred microliters of antagomir -942 (diluted in PBS at 2 mg/ml) or control antagomir was administrated intratumourally 3 times per week for 2 weeks, starting when the average volume of grown tumours reached approximately 50 mm 3 . For dosages injection assay, the NOD/SCID mice were randomly divided into 3 groups (n= 6 per group). Indicated cells of 3 dosages (1 × 10 4 , 1 × 10 3 , and 1 × 10 2 ) were inoculated subcutaneously with matrigel (final concentration of 25%) into the inguinal folds of NOD/SCID mice. Tumour volume was calculated using the equation (Length*Weight 2 )/2. On day 40, tumours were detected by an IVIS imaging system (Caliper), then animals were euthanized, and the tumours were excised, weighed and paraffin-embedded.
Animal studies
tumour sphere formation assays
Five hundred cells were seeded in 6-well ultra-low cluster plates and 10 or 20 cells were seeded in 24-well ultra-low cluster plates for 10 days. Spheres were cultured in DMEM/F12 serum-free medium (Invitrogen, USA) supplemented with 2% B27 (Invitrogen, USA), 20 ng/ ml EGF, 20 ng/ml bFGF, and 5 μg/ml insulin (PeproTech, USA).
Flow cytometric analysis
Flow cytometric analysis or flow cytometric cell sorting was conducted using phycoerythrin (PE)-conjugated monoclonal mouse anti-human CD90 (Miltenyi Biotec GmbH, Germany). Samples were analyzed and sorted on BD FACS Canto II and FACS Aria I, respectively (BD Biosciences, USA) with data analyzed using FlowJo software (Tree Star Inc, USA).
chromatin Immunoprecipitation (chIP)
Cells (2×10 6 ) in a 100-mm culture dish were treated with 1% formaldehyde to cross-link proteins to DNA. The cell lysates were sonicated to shear DNA to sizes of 300-1000 bp. Equal aliquots of chromatin supernatants were incubated with 1 μg of anti-c-myc antibody (Abcam, Cambridge, MA) or an anti-IgG antibody (Millipore, Billerica, MA) overnight at 4°C with rotation. After reverse cross-link of protein/DNA complexes to free DNA, PCR was performed.
bioinformatics analysis
The following on-line software programs were used for bioinformatics analysis: The Cancer Genome Atlas (TCGA) (http://cancergenome.nih.gov/ ); TargetScan 6.2 (http://www. targetscan.org/); and miRanda (http://www. microrna.org/ microrna /getGene Form.do).
statistical analysis
All statistical analyses were carried out using SPSS 18.0 statistical software. The Kaplan-Meier method was used to establish survival curves, and the survival differences were compared using the log-rank test. Continuous data were compared using Student's 2-tailed t-test. Multivariate statistical analysis was performed using a Cox regression model. In all cases, P < 0.05 was considered statistically significant.
study approval
For the use of materials for research purposes, prior patient consent was obtained, and study approval was granted by the affiliated hospital of academy of military medical sciences and Cancer Center Institution Board. All animal studies were approved by the Affiliated hospital of Academy of military medical sciences Institutional Animal Care and Use Committee.
